

STRONG
KNOWLEDGE
BASE.

MANUFACTURING
SCALE
AND EFFICIENCY.

OPERATIONAL
EXCELLENCE.

ENDURING
CUSTOMER
RELATIONSHIPS.



IN A RAPIDLY CHANGING PHARMACEUTICAL
LANDSCAPE, NEW ALTITUDES OF PERFORMANCE
AND PROGRESS NEED TO BE CONSTANTLY
IDENTIFIED AND ACHIEVED.



AT GRANULES, ASCENDING
EACH ALTITUDE IS
PREPARATION FOR
THE NEXT.

CHALLENGING OURSELVES

CHALLENGES OPEN NEW HORIZONS OF OPPORTUNITY AND THAT'S WHAT HELPED US ADVANCE SINCE INCEPTION.



For nearly three decades, we have been focused on manufacturing cost-effective drugs for quality-conscious customers.

Granules India is a leading global provider of Paracetamol, Metformin, Ibuprofen, Guaifenesin and Methocarbamol. We produce all three components of the pharmaceutical manufacturing value chain including Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages (FDs).

We have state-of-the-art manufacturing facilities that are catered to quality-conscious customers. Our facilities are among the largest in the world so we can supply to our customers' growing needs. We serve customers in more than 65 countries, with offices in India, U.S., U.K., Colombia and China.

OUR CORE VALUES



7 manufacturing sites



Geographic presence across
65+ countries



Team strength of
1,500+ people



Possesses the world's largest
PFI facility

CUSTOMER FOCUSED

We focus our energies towards understanding and addressing customer expectations.

CONTINUOUS IMPROVEMENT

We systematically enhance our products, processes and services.

QUALITY

We strive to preserve high standards in all our products and processes.

INTEGRITY


We maintain consistency in our values, means and actions in conducting our business.


TEAM


We work towards building a conducive environment helping individuals realise their maximum potential.

INNOVATION CREATES POSSIBILITIES

OUR INNOVATIVE SOLUTIONS PROVIDE OUR CUSTOMERS WITH
A COMPETITIVE EDGE.



	Produces PFIs through a 6 ton batch size
	Serves more than 300 customers
	Possesses a product portfolio comprising 20 single and multiple active PFIs




We pioneered the concept of commercialising the PFIs. Earlier, manufacturing PFIs was a costly process for a finished dosage producer, but outsourcing this process has substantially reduced costs. At Granules, our level-next innovation has made this possible.

Our unique concept was to create a 'ready-to-compress' mix of APIs and excipients that finished dosage manufacturers could compress in a one-step process. The proposition of outsourcing PFIs has transformed the conventional pharmaceutical manufacturing model by offering customers significant savings, fewer handling and regulatory hurdles and higher efficiency.

INNOVATION GENERATES INCREMENTAL VALUE

OUTSOURCING OF PFIs HAS RESULTED IN SEVERAL OPERATIONAL AND FINANCIAL BENEFITS FOR OUR CUSTOMERS AT LARGE.



SIMPLIFIES SUPPLY CHAIN MANAGEMENT

PFIs simplify supply chain complexities for our customers since they need to deal with only one vendor instead of multiple vendors. In addition, their working capital costs also decline.

REDUCES VENDOR DEVELOPMENT COST

Customers save a significant amount on vendor development costs since they do not need to qualify multiple vendors for the various materials and processes required to manufacture PFIs.

LOWERS TESTING COSTS

Our customers conduct a single test resulting in significant savings. Besides, our volume based manufacturing (six-ton blender) and bigger batch size ensures consistency in the quality of deliverables to the customers.

SAVES ON TECHNICAL RESOURCES

Our ability to manufacture complex PFIs such as Ibuprofen and Ciprofloxacin allows our customers to avoid large expenditures on pre-formulation studies and process development.

REDUCES CAPITAL EXPENDITURE SIGNIFICANTLY

Setting up a PFI facility comprises more than 80% of the total investments in a normal oral solid dosage manufacturing facility. Our expertise to deliver PFI allows our customers to stay asset light.

EXPANDING SCALE WITH AGILITY

IN ORDER TO MEET THE NEEDS OF OUR CUSTOMERS, WE HAVE BEEN EXPANDING CAPACITY ACROSS OUR VALUE CHAIN. OUR OBJECTIVE IS TO LEVERAGE ECONOMIES OF SCALE TO ADD FURTHER VALUE TO OUR CUSTOMERS.




In the API, we are among the largest quality-conscious manufacturers of Paracetamol, Ibuprofen, Metformin, Guaifenesin and Methocarbamol.

Granules also possesses the world's largest granulation site with an industry leading six-ton batch size. In addition, our Finished Dosage site is one of the largest single-site facilities in the world. All our facilities are certified by leading regulatory agencies, including the U.S. FDA, EDQM, Informed and MHRA.



INTEGRATION MODULE




REGULATORY APPROVALS

[U.S. FDA](#)
[MHRA](#)
[EDQM](#)
[Informed \(EU\)](#)
[TPD Canada](#)
[KFDA](#)
[MCC](#)
[Russian Health Authorities](#)
[WHO GMP](#)

STRENGTH THROUGH PARTNERSHIPS

WE'VE CREATED STRONG ALLIANCES THAT ARE IN CONSONANCE WITH OUR BUSINESS PHILOSOPHY.



In November 2013, Granules signed a definitive agreement for the acquisition of Auctus Pharma, a leading API manufacturer. The facility has approvals from leading regulatory agencies including the U.S. FDA, EDQM, Health Canada and KFDA

The company has products in therapeutic spaces such as antihistaminic, antihypertensive, antithrombotic, anticonvulsant and antifungal as well as several other spaces.



The company's regulatory filings include 8 European filings, 4 USDMFs, 3 South Korean DMFs, 3 IDL China, 2 Health Canada, 1 Italy and 1 Spain.

This acquisition strengthens Granules' portfolio and opens up growth opportunities in the integrated Generics space in coming years.

Granules will provide finished dosages of the new APIs in order to provide supply security and more flexibility for our customers.





Granules Omnicem is a **50:50** joint venture focused on the CRAMs space

Granules Biocause is a **50:50** joint venture in the Ibuprofen space

We also have two partnerships with renowned global pharma companies to complement our capabilities. These alliances enable us to drive further value for our customers.

GRANULES BIOCAUSE

A joint-venture with Hubei Biocause, is among the premier Ibuprofen manufacturers. This JV provides us with an access to high quality Ibuprofen API and strengthens our PFI and Finished Dosages.




GRANULES OMNICHEM

A joint-venture with Ajinomoto OmniChem was formed in 2011. Our JV is focused on the CRAMS space and assists innovator companies. Granules OmniChem is unique because it combines two companies that are known for high-quality products, extensive technological expertise and deep relationships with leading pharmaceutical companies.

Granules Omnicem is focused on complex APIs in therapeutic sectors including cardiovascular, CNS and oncology.

ENDURING CUSTOMER RELATIONSHIPS

CUSTOMER-CENTRICITY LIES AT THE CORE OF OUR PRODUCTS. THE RESULT IS ENDURING CUSTOMER RELATIONSHIPS.



We believe our association with customers should be a partnership instead of focusing on a single transaction. We add value to our partnerships by offering several initiatives.

- Provide customers with access to ANDAs and dossiers
- Ensure that customers can consult specialists, who can assist them with their technical needs such as, finding the appropriate API
- Offer value-added products such as rapid-release caplets and bi-layer tablets
- Provide access to our technical team, which will facilitate in streamlining production processes





GRANULES INDIA LIMITED

Corporate Office

My Home Hub
Second Floor, Third Block
Madhapur, Hyderabad - 500 081
Ph.No: +91 40 6676 0000
Fax: +91 40 2311 5145

North America Office

Mani Swaminathan
mani@granulesindia.com
Rajesh Narra
rajesh.narra@granulesindia.com

Europe Office

Mike Frude
mfrude@granulesindia.com
Sasi Bhushan
sasi.bhushan@granulesindia.com

Asia, Middle East & Africa (AMEA) Office

BNR Prasad
bnrprasad@granulesindia.com
Durga Kiran
Durgakiran.makke@granulesindia.com

Latin America Office

Stefan Lohle
slohle@granulesindia.com
Naveed Yousuf
naveed@granulesindia.com

India Office

Lakshma Reddy
Lakshma.reddy@granulesindia.com
BNR Prasad
bnrprasad@granulesindia.com

For all other general enquiries

mail@granulesindia.com

www.granulesindia.com